Published in Sci Rep on September 07, 2016
A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection | NCT01829971
Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods (2001) 414.27
The hallmarks of cancer. Cell (2000) 113.05
Comprehensive molecular portraits of human breast tumours. Nature (2012) 47.39
Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A (2002) 32.26
Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A (2004) 28.29
A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell (2006) 27.36
The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov (2012) 26.98
miRBase: integrating microRNA annotation and deep-sequencing data. Nucleic Acids Res (2010) 25.85
Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal (2013) 19.54
The role of site accessibility in microRNA target recognition. Nat Genet (2007) 18.52
The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev (2008) 15.01
Endogenous human microRNAs that suppress breast cancer metastasis. Nature (2008) 14.37
The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature (2012) 11.91
Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest (2008) 10.74
Treatment of HCV infection by targeting microRNA. N Engl J Med (2013) 9.91
miRWalk--database: prediction of possible miRNA binding sites by "walking" the genes of three genomes. J Biomed Inform (2011) 8.50
Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta (2006) 7.33
KEGG as a reference resource for gene and protein annotation. Nucleic Acids Res (2015) 6.44
Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 3' kinase/AKT pathways. Oncogene (2005) 5.50
In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models. Clin Cancer Res (2009) 4.81
The microcosmos of cancer. Nature (2012) 4.50
The PTEN-PI3K pathway: of feedbacks and cross-talks. Oncogene (2008) 4.39
Predicting effective microRNA target sites in mammalian mRNAs. Elife (2015) 4.30
G12-G13-LARG-mediated signaling in vascular smooth muscle is required for salt-induced hypertension. Nat Med (2007) 4.26
Class I PI3K in oncogenic cellular transformation. Oncogene (2008) 3.90
PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer. Oncogene (2011) 3.59
The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer. Clin Cancer Res (2012) 3.36
microRNA-associated progression pathways and potential therapeutic targets identified by integrated mRNA and microRNA expression profiling in breast cancer. Cancer Res (2011) 3.25
mTORC1 and mTORC2 regulate EMT, motility, and metastasis of colorectal cancer via RhoA and Rac1 signaling pathways. Cancer Res (2011) 3.12
Epithelial mesenchymal transition traits in human breast cancer cell lines. Clin Exp Metastasis (2008) 2.86
E-cadherin transcriptional downregulation by promoter methylation but not mutation is related to epithelial-to-mesenchymal transition in breast cancer cell lines. Br J Cancer (2006) 2.74
miRNA-mRNA integrated analysis reveals roles for miRNAs in primary breast tumors. PLoS One (2011) 2.70
The polycomb group protein Bmi-1 represses the tumor suppressor PTEN and induces epithelial-mesenchymal transition in human nasopharyngeal epithelial cells. J Clin Invest (2009) 2.52
Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer. Cell (2015) 2.39
DIANA-microT web server v5.0: service integration into miRNA functional analysis workflows. Nucleic Acids Res (2013) 2.32
Pim kinases promote cell cycle progression by phosphorylating and down-regulating p27Kip1 at the transcriptional and posttranscriptional levels. Cancer Res (2008) 2.20
Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway. Cancer Chemother Pharmacol (2013) 2.09
Differentiation state and invasiveness of human breast cancer cell lines. Breast Cancer Res Treat (1994) 2.05
MicroRNA-7 inhibits tumor growth and metastasis by targeting the phosphoinositide 3-kinase/Akt pathway in hepatocellular carcinoma. Hepatology (2012) 1.96
A link between mir-100 and FRAP1/mTOR in clear cell ovarian cancer. Mol Endocrinol (2010) 1.94
Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer. Cancer Treat Rev (2013) 1.73
Activated mitogen-activated protein kinase expression during human breast tumorigenesis and breast cancer progression. Clin Cancer Res (2002) 1.71
Global microRNA level regulation of EGFR-driven cell-cycle protein network in breast cancer. Mol Syst Biol (2012) 1.69
Modeling ERBB receptor-regulated G1/S transition to find novel targets for de novo trastuzumab resistance. BMC Syst Biol (2009) 1.63
miR-34: from bench to bedside. Oncotarget (2014) 1.59
Phosphatidylinositol-3 kinase dependent pathways: the role in control of cell growth, survival, and malignant transformation. Biochemistry (Mosc) (2000) 1.52
MicroRNA-200c represses migration and invasion of breast cancer cells by targeting actin-regulatory proteins FHOD1 and PPM1F. Mol Cell Biol (2011) 1.49
BRAF and RAS oncogenes regulate Rho GTPase pathways to mediate migration and invasion properties in human colon cancer cells: a comparative study. Mol Cancer (2011) 1.47
MicroRNA expression aberration as potential peripheral blood biomarkers for schizophrenia. PLoS One (2011) 1.47
PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types. Cancer Chemother Pharmacol (2013) 1.46
Targeting the AKT protein kinase for cancer chemoprevention. Mol Cancer Ther (2007) 1.45
A regulatory circuit of miR-148a/152 and DNMT1 in modulating cell transformation and tumor angiogenesis through IGF-IR and IRS1. J Mol Cell Biol (2012) 1.42
MicroRNA-21 suppresses PTEN and hSulf-1 expression and promotes hepatocellular carcinoma progression through AKT/ERK pathways. Cancer Lett (2013) 1.38
ERK negatively regulates the epidermal growth factor-mediated interaction of Gab1 and the phosphatidylinositol 3-kinase. J Biol Chem (2002) 1.35
Role of PRAS40 in Akt and mTOR signaling in health and disease. Am J Physiol Endocrinol Metab (2012) 1.31
p38 Mitogen-activated protein kinase mediates the transcriptional induction of the atrial natriuretic factor gene through a serum response element. A potential role for the transcription factor ATF6. J Biol Chem (1998) 1.28
A systematic evaluation of miRNA:mRNA interactions involved in the migration and invasion of breast cancer cells. J Transl Med (2013) 1.25
miR-10b*, a master inhibitor of the cell cycle, is down-regulated in human breast tumours. EMBO Mol Med (2012) 1.14
Acquisition of epithelial-mesenchymal transition phenotype and cancer stem cell-like properties in cisplatin-resistant lung cancer cells through AKT/β-catenin/Snail signaling pathway. Eur J Pharmacol (2013) 1.11
Akt2: a role in breast cancer metastasis. Breast Cancer Res (2003) 1.10
Androgen receptor is the key transcriptional mediator of the tumor suppressor SPOP in prostate cancer. Cancer Res (2014) 1.07
EZH2 is regulated by ERK/AKT and targets integrin alpha2 gene to control Epithelial-Mesenchymal Transition and anoikis in colon cancer cells. Int J Biochem Cell Biol (2012) 1.05
Genomic Determinants of PI3K Pathway Inhibitor Response in Cancer. Front Oncol (2012) 1.05
Downregulation of miR-31, miR-155, and miR-564 in chronic myeloid leukemia cells. PLoS One (2012) 1.00
MicroRNA-497 suppresses angiogenesis by targeting vascular endothelial growth factor A through the PI3K/AKT and MAPK/ERK pathways in ovarian cancer. Oncol Rep (2014) 0.97
MicroRNA-519a is a novel oncomir conferring tamoxifen resistance by targeting a network of tumour-suppressor genes in ER+ breast cancer. J Pathol (2014) 0.96
Integrated genomic analysis of triple-negative breast cancers reveals novel microRNAs associated with clinical and molecular phenotypes and sheds light on the pathways they control. BMC Genomics (2013) 0.95
Pharmacological inhibition of polycomb repressive complex-2 activity induces apoptosis in human colon cancer stem cells. Exp Cell Res (2013) 0.94
Prognostic and predictive significance of MYC and KRAS alterations in breast cancer from women treated with neoadjuvant chemotherapy. PLoS One (2013) 0.94
Lack of evidence for KRAS oncogenic mutations in triple-negative breast cancer. BMC Cancer (2010) 0.93
Translocation and activation of AKT2 in response to stimulation by insulin. J Cell Biochem (1998) 0.91
MicroRNAs: master regulators of drug resistance, stemness, and metastasis. J Mol Med (Berl) (2014) 0.91
Concomitant targeting of tumor cells and induction of T-cell response synergizes to effectively inhibit trastuzumab-resistant breast cancer. Cancer Res (2012) 0.90
A cell of origin gene signature indicates human bladder cancer has distinct cellular progenitors. Stem Cells (2014) 0.90
Isolation and characterization of SRF accessory proteins. Philos Trans R Soc Lond B Biol Sci (1993) 0.88
Integration of molecular targeted therapy with radiation in head and neck cancer. Pharmacol Ther (2013) 0.86
Hypoxia promotes glycogen synthesis and accumulation in human ovarian clear cell carcinoma. Int J Oncol (2012) 0.84
Breast cancer cell invasion mediated by Gα12 signaling involves expression of interleukins-6 and -8, and matrix metalloproteinase-2. J Mol Signal (2014) 0.83
ErbB2-intronic microRNA-4728: a novel tumor suppressor and antagonist of oncogenic MAPK signaling. Cell Death Dis (2015) 0.79
Biomarker-guided sequential targeted therapies to overcome therapy resistance in rapidly evolving highly aggressive mammary tumors. Cell Res (2014) 0.79
Selective activation of human atrial Galpha12 and Galpha13 by Galphaq-coupled angiotensin and endothelin receptors. J Cardiovasc Pharmacol (2007) 0.79
The combinatorial activation of the PI3K and Ras/MAPK pathways is sufficient for aggressive tumor formation, while individual pathway activation supports cell persistence. Oncotarget (2015) 0.78
MicroRNA-214 acts as a potential oncogene in breast cancer by targeting the PTEN-PI3K/Akt signaling pathway. Int J Mol Med (2016) 0.77
MiR-564 functions as a tumor suppressor in human lung cancer by targeting ZIC3. Biochem Biophys Res Commun (2015) 0.76